Publications by authors named "Terrance J Y Ku"
EBioMedicine
October 2020
Article Synopsis
- Ex-vivo lung perfusion (EVLP) was used to test the effects of administering the anti-CD20 monoclonal antibody Rituximab on donor lungs, aiming to reduce B-cell populations and potentially lower the risk of post-transplant complications like cancer from Epstein-Barr virus (EBV).
- Rituximab was successfully delivered to the lungs, showing significant reductions in CD20+ B-cells in both lung and lymph node tissues, with no safety concerns noted from inflammation or injury markers.
- The study indicates that Rituximab may effectively deplete B-cells during the EVLP process, which could improve outcomes for lung transplant patients.
